ALXN1840’s Triumph: Neurologic Hope in Wilson Disease
Clinically meaningful neurologic worsening at Week 48 occurred in 25% of patients on standard of care versus 9% on...
Xenon Presents Azetukalner Phase 3 Seizure Study Results
Azetukalner cut monthly focal-onset seizure frequency by a median 53.2% at 25 mg and 34.5% at 15 mg over...
New Zoldonrasib Clinical Data for KRAS G12D Lung Cancer
In a Phase 1 dose-expansion cohort of previously treated KRAS G12D non-small cell lung cancersmall cell lung cancer, zoldonrasib...
meiragtx Announces Positive 3-Year Xerostomia Trial Data
Three-year follow-up from MeiraGTx’s Phase 1 AQUAx study showed sustained, clinically meaningful improvements in patient-reported xerostomia symptoms and persistent...
Remedy Plan Therapeutics Announces AACR 2026 Presentations
Remedy Plan Therapeutics will bring a broad slate of AACR presentations centered on RPT1G, its “hyperbolic” NAMPT inhibitor now...
Bioxodes Shares Pivotal Trial Design for BIOX-101 in ICH
Bioxodes is moving BIOX-101 into an adaptive Phase 2b/3 study in intracerebral hemorrhage with functional outcome (mRS) as the...
AIM Plans Pivotal Phase 3 Trial for Pancreatic Cancer
In late-stage pancreatic ductal adenocarcinoma, rintatolimod (Ampligen) has generated early clinical signals across multiple settings: a Dutch named-patient program...
Surging Storm Therapeutics Secures $56M for Sarcoma Drug
In earlier-stage testing, STC-15, an oral METTL3 inhibitor, produced durable tumor regressions across multiple sarcoma subtypes as monotherapy. Building...
Ewing Sarcoma’s EWS::FLI1 Trial Just Showed What Precision Oncology Has Been Promising for a Decade
A Nature Medicine phase 1/2 trial of trabectedin plus low-dose irinotecan targeting EWS::FLI1 in Ewing sarcoma signals a new...
The Imaging Gap in GLP-1 Trials: Why the Most Important Data May Not Be in Your Protocol
Professor Mikael Boesen Professor of Musculoskeletal Radiology & Head of Imaging Research, Copenhagen University Hospital Bispebjerg and Frederiksberg A...